Inarigivir ammonium

Research use only, not for human use.

Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.

Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.(In Vitro):Inarigivir is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B.(In Vivo):Administration of 100 mg/kg/day Inarigivir (ip) significantly reduces viral DNA in the liver and shows anti-HBV activity while serum HBV DNA is not reduced. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values.

ORI-9020 ammonium; SB-9200 ammonium

Microbiology/Virology

HBV

HIF/HIF Prolyl-Hydroxylase

——

——

2172788-92-8

604.5

C20H29N8O10PS

>98% (HPLC)

——

NC1=C(N=CN2[C@@H]3O[C@H](COP(O[C@H]4[C@@H](OC)[C@H](N5C=CC(NC5=O)=O)O[C@@H]4CO)(S)=O)[C@@H](O)C3)C2=NC=N1.N

——

(-20℃)

With Ice Pack

≥ 2 years